Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review

World Journal of Gastroenterology

Volumn 20, Issue 40, 2014, Pages 14598-14614

  Sun, Hsin Yun ^a   Sheng, Wang Huei ^a   Tsai, Mao Song ^b   Lee, Kuan Yeh ^a   Chang, Sui Yuan ^a,c   Hung, Chien Ching ^a,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Nucleoside reverse transcriptase inhibitor; Seroepidemiology; Sexually transmitted diseases; Vaccination; Viral hepatitis

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; EMTRICITABINE; ENTECAVIR; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG DOSE REGIMEN; DRUG SAFETY; END STAGE LIVER DISEASE; ETHNIC DIFFERENCE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; META ANALYSIS (TOPIC); MIXED INFECTION; MORTALITY; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEROPREVALENCE; SEXUAL TRANSMISSION; VACCINATION; VIRUS TRANSMISSION; DISEASE COURSE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; PATHOGENICITY; REMISSION; RISK ASSESSMENT; RISK FACTOR; TRANSMISSION; TREATMENT OUTCOME;

ANTI-HIV AGENTS; COINFECTION; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; REMISSION INDUCTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84910667315     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i40.14598     Document Type: Review

References (172)

1. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7: 402-409 [PMID: 17521593 DOI: 10.1016/S1473-3099(07)70135-4]
2. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection - a global challenge. N Engl J Med 2012; 366: 1749-1752 [PMID: 22571198 DOI: 10.1056/NEJMp1201796]
3. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601 [PMID: 15802978]
4. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926 [PMID: 12493258]
5. Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, Hung CC, Chen MY, Chang SC. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45: 1221-1229 [PMID: 17918088 DOI: 10.1086/522173]
6. Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, Peel SA, Jagodzinski LL, Weintrob AC, Ganesan A, Wortmann G, Crum-Cianflone NF, Maguire JD, Landrum ML. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012; 205: 185-193 [PMID: 22147794 DOI: 10.1093/infdis/jir720]
7. Tsai MS, Chang SY, Lo YC, Yang CJ, Sun HY, Liu WC, Wu PY, Hung CC. Hepatitis B virus (HBV) coinfection accelerates immunologic progression in patients with primary HIV infection in an area of hyperendemicity for HBV infection. J Infect Dis 2013; 208: 1184-1186 [PMID: 23840045 DOI: 10.1093/infdis/jit299]
8. Wandeler G, Gsponer T, Bihl F, Bernasconi E, Cavassini M, Kovari H, Schmid P, Battegay M, Calmy A, Egger M, Furrer H, Rauch A. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis 2013; 208: 1454-1458 [PMID: 23901088 DOI: 10.1093/infdis/jit351]
9. World Health Organization. Hepatitis B. Available from: URL: http//www.who.int/mediacentre/factsheets/fs204/en/
10. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49: S138-S145 [PMID: 19399813 DOI: 10.1002/hep.22883]
11. Denis F, Adjide CC, Rogez S, Delpeyroux C, Rogez JP, Weinbreck P. [Seroprevalence of HBV, HCV and HDV hepatitis markers in 500 patients infected with the human immunodeficiency virus]. Pathol Biol (Paris) 1997; 45: 701-708 [PMID: 9538467]
12. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571-577 [PMID: 12898445 DOI: 10.1086/377135]
13. Roca B, Suarez I, Gonzalez J, Garrido M, de la Fuente B, Teira R, Geijo P, Cosin J, Perez-Cortes S, Galindo MJ, Lozano F, Domingo P, Viciana P, Ribera E, Vergara A, Sánchez T. Hepatitis C virus and human immunodeficiency virus coinfection in Spain. J Infect 2003; 47: 117-124 [PMID: 12860144]
14. Rosenblum L, Darrow W, Witte J, Cohen J, French J, Gill PS, Potterat J, Sikes K, Reich R, Hadler S. Sexual practices in the transmission of hepatitis B virus and prevalence of hepatitis delta virus infection in female prostitutes in the United States. JAMA 1992; 267: 2477-2481 [PMID: 1573724]
15. Osmond DH, Charlebois E, Sheppard HW, Page K, Winkelstein W, Moss AR, Reingold A. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. J Infect Dis 1993; 167: 66-71 [PMID: 8418184]
16. Piot P, Goilav C, Kegels E. Hepatitis B: transmission by sexual contact and needle sharing. Vaccine 1990; 8 Suppl: S37-40; discussion S41-3 [PMID: 2183516]
17. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219 [PMID: 22273662 DOI: 10.1016/j.vaccine.2011.12.116]
18. Su WJ, Liu CC, Liu DP, Chen SF, Huang JJ, Chan TC, Chang MH. Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. J Infect Dis 2012; 205: 757-762 [PMID: 22262790 DOI: 10.1093/infdis/jir852]
19. McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C, Parkinson AJ. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011; 54: 801-807 [PMID: 21618565 DOI: 10.1002/hep.24442]
20. Chen SM, Kung CM, Yang WJ, Wang HL. Efficacy of the nationwide hepatitis B infant vaccination program in Taiwan. J Clin Virol 2011; 52: 11-16 [PMID: 21767983 DOI: 10.1016/j.jcv.2011.06.012]
21. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859 [PMID: 9197213 DOI: 10.1056/NEJM199706263362602]
22. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013; 310: 974-976 [PMID: 24002285 DOI: 10.1001/jama.2013.276701]
23. Sun HY, Ko WC, Tsai JJ, Lee HC, Liu CE, Wong WW, Su SC, Ho MW, Cheng SH, Yang CH, Lin YH, Miao WJ, Sheng WH, Hung CC. Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination. Am J Gastroenterol 2009; 104: 877-884 [PMID: 19259078 DOI: 10.1038/ajg.2008.159]
24. Sun HY, Cheng CY, Lee NY, Yang CJ, Liang SH, Tsai MS, Ko WC, Liu WC, Wu PY, Wu CH, Lin HH, Hung CC. Seroprevalence of hepatitis B virus among adults at high risk for HIV transmission two decades after implementation of nationwide hepatitis B virus vaccination program in Taiwan. PLoS One 2014; 9: e90194 [PMID: 24587275 DOI: 10.1371/journal.pone.0090194]
25. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009; 3: 334-342 [PMID: 19669359 DOI: 10.1007/s12072-008-9112-z]
26. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 2010; 40: 14-30 [PMID: 20156297 DOI: 10.1111/j.1872-034X.2009.00601.x]
27. Olinger CM, Jutavijittum P, Hübschen JM, Yousukh A, Samountry B, Thammavong T, Toriyama K, Muller CP. Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis 2008; 14: 1777-1780 [PMID: 18976569 DOI: 10.3201/eid1411.080437]
28. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, Nakayoshi T, Wakuta M, Miyakawa Y, Mizokami M. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009; 83: 10538-10547 [PMID: 19640977 DOI: 10.1128/JVI.00462-09]
29. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40: 1207-1209 [PMID: 11923332]
30. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123: 1848-1856 [PMID: 12454842 DOI: 10.1053/gast.2002.37041]
31. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39: 1694-1701 [PMID: 15185311 DOI: 10.1002/hep.20240]
32. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-559 [PMID: 10702206]
33. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005; 43: 411-417 [PMID: 16006001 DOI: 10.1016/j.jhep.2005.03.018]
34. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-1143 [PMID: 18695135 DOI: 10.1093/jnci/djn243]
35. Yuen MF, Tanaka Y, Mizokami M, Yuen JC, Wong DK, Yuan HJ, Sum SM, Chan AO, Wong BC, Lai CL. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis 2004; 25: 1593-1598 [PMID: 15090469 DOI: 10.1093/carcin/bgh172]
36. Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, Sung JJ. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498 [PMID: 15361502 DOI: 10.1136/gut.2003.033324]
37. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-334 [PMID: 12557138 DOI: 10.1053/gast.2003.50053]
38. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845]
39. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 998-1002 [PMID: 11131465]
40. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-1430 [PMID: 12447868 DOI: 10.1053/jhep.2002.37139]
41. Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, Häussinger D. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009-1013 [PMID: 15951551 DOI: 10.1136/gut.2004.060327]
42. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-2179.e1-4 [PMID: 19303414 DOI: 10.1053/j.gastro.2009.03.006]
43. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 1267-1273 [PMID: 14578866 DOI: 10.1053/jhep.2003.50458]
44. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002; 36: 303-304 [PMID: 11830346]
45. Yuen MF, Wong DK, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AO, Wang BC, Lai CL. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003; 8: 531-534 [PMID: 14760886]
46. Chan HL, Wong ML, Hui AY, Chim AM, Tse AM, Hung LC, Chan FK, Sung JJ. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003; 9: 2695-2697 [PMID: 14669315]
47. Westland C, Delaney W, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003; 125: 107-116 [PMID: 12851876]
48. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 447-454 [PMID: 18080339 DOI: 10.1002/hep.22075]
49. Dao HY, Joshi R. Non-A Hepatitis B Genotypes are Associated with More Liver Fibrosis in HIV/HBV Patients. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008). San Francisco, USA, 2008
50. Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte Ad, Flisiak R, Lundgren J. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother 2010; 65: 548-555 [PMID: 20051475 DOI: 10.1093/jac/dkp479]
51. Thibault V, Gaudy-Graffin C, Colson P, Gozlan J, Schnepf N, Trimoulet P, Pallier C, Saune K, Branger M, Coste M, Thoraval FR. Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study. Virol J 2013; 10: 87 [PMID: 23497042 DOI: 10.1186/1743-422X-10-87]
52. Lacombe K, Massari V, Girard PM, Serfaty L, Gozlan J, Pialoux G, Mialhes P, Molina JM, Lascoux-Combe C, Wendum D, Carrat F, Zoulim F. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 2006; 20: 419-427 [PMID: 16439876 DOI: 10.1097/01.aids.0000200537.86984.0e]
53. Calin R, Guiguet M, Desire N, Imbert-Bismut F, Munteanu M, Poynard T, Valantin MA, Stitou H, Katlama C, Thibault V. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up. J Clin Virol 2013; 58: 408-414 [PMID: 23958588 DOI: 10.1016/j.jcv.2013.07.018]
54. Sheng WH, Hung CC, Chang SY, Liu CJ, Chen MY, Hsieh SM, Kao JH, Chen PJ, Chang SC. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy. Clin Infect Dis 2012; 54: 548-555 [PMID: 22156858 DOI: 10.1093/cid/cir851]
55. Israël N, Hazan U, Alcami J, Munier A, Arenzana-Seisdedos F, Bachelerie F, Israël A, Virelizier JL. Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens. J Immunol 1989; 143: 3956-3960 [PMID: 2574206]
56. Twu JS, Chu K, Robinson WS. Hepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1. Proc Natl Acad Sci USA 1989; 86: 5168-5172 [PMID: 2740349]
57. Gómez-Gonzalo M, Carretero M, Rullas J, Lara-Pezzi E, Aramburu J, Berkhout B, Alcamí J, López-Cabrera M. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem 2001; 276: 35435-35443 [PMID: 11457829 DOI: 10.1074/jbc.M103020200]
58. Eskild A, Magnus P, Petersen G, Sohlberg C, Jensen F, Kittelsen P, Skaug K. Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS 1992; 6: 571-574 [PMID: 1388879]
59. Scharschmidt BF, Held MJ, Hollander HH, Read AE, Lavine JE, Veereman G, McGuire RF, Thaler MM. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992; 117: 837-838 [PMID: 1416559]
60. Sinicco A, Raiteri R, Sciandra M, Bertone C, Lingua A, Salassa B, Gioannini P. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: no evidence of faster progression to AIDS. Scand J Infect Dis 1997; 29: 111-115 [PMID: 9181644]
61. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991; 163: 1138-1140 [PMID: 2019762]
62. Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, Schable CA, Coleman PJ, Ostrow DN, Francis DP. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163: 454-459 [PMID: 1825315]
63. Oshitani H, Kasolo FC, Mpabalwani M, Mizuta K, Luo NP, Suzuki H, Numazaki Y. Prevalence of hepatitis B antigens in human immunodeficiency virus type 1 seropositive and seronegative pregnant women in Zambia. Trans R Soc Trop Med Hyg 1996; 90: 235-236 [PMID: 8758060]
64. Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, Leroy V, Dabis F, Rouzioux C. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study. J Med Virol 2004; 74: 34-40 [PMID: 15258966 DOI: 10.1002/jmv.20143]
65. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-1310 [PMID: 10094979 DOI: 10.1002/hep.510290447]
66. Sheng WH, Chen MY, Hsieh SM, Hsiao CF, Wang JT, Hung CC, Chang SC. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004; 38: 1471-1477 [PMID: 15156487 DOI: 10.1086/420744]
67. Sheng WH, Hung CC, Kao JH, Chang SY, Chen MY, Hsieh SM, Chen PJ, Chang SC. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. Clin Infect Dis 2007; 44: 988-995 [PMID: 17342655 DOI: 10.1086/511867]
68. Hung CC, Wu SM, Lin PH, Sheng WH, Yang ZY, Sun HY, Tsai MS, Lee KY, Huang MS, Chang SF, Su YC, Liu WC, Chang SY. Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection. Clin Infect Dis 2014; 58: 1625-1633 [PMID: 24599769]
69. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/Hep.23190]
70. Marcellin P, Boyer N, Colin JF, Martinot-Peignoux M, Lefort V, Matheron S, Erlinger S, Benhamou JP. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 1993; 34: S106 [PMID: 8314471]
71. Johnson RM, Ristig MB, Overton ET, Lisker-Melman M, Cummings OW, Aberg JA. Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV Clin Trials 2007; 8: 173-181 [PMID: 17621464 DOI: 10.1310/hct0803-173]
72. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-723 [PMID: 11551579]
73. Matthews GV, Seaberg EC, Avihingsanon A, Bowden S, Dore GJ, Lewin SR, Sasadeusz J, Revill PA, Littlejohn M, Hoy JF, Finlayson R, Ruxrungtham K, Saulynas M, Locarnini S, Thio CL. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis 2013; 56: e87-e94 [PMID: 23315316 DOI: 10.1093/cid/cit002]
74. Soriano V, Tuma P, Vispo E, Labarga P, Fernández JV, Medrano J, Barreiro P. Hepatitis B in HIV patients: what is the current treatment and what are the challenges? J HIV Ther 2009; 14: 13-18 [PMID: 19731560]
75. Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet B. Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens. Antivir Ther 2008; 13: 231-240 [PMID: 18505174]
76. Taburet AM, Piketty C, Chazallon C, Vincent I, Gérard L, Calvez V, Clavel F, Aboulker JP, Girard PM. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091-2096 [PMID: 15155205 DOI: 10.1128/AAC.48.6.2091-2096.2004]
77. van Maarseveen NM, Wensing AM, de Jong D, Beilhartz GL, Obikhod A, Tao S, Pingen M, Arends JE, Hoepelman AI, Schinazi RF, Götte M, Nijhuis M. Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans. Antivir Ther 2011; 16: 1123-1130 [PMID: 22024528 DOI: 10.3851/IMP1912]
78. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, Jacobson JM, Johnson VA, Pollard RB, Rooney JF, Sherman KE, Swindells S, Polsky B. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44: 1110-1116 [PMID: 17058225 DOI: 10.1002/hep.21388]
79. Ratcliffe L, Beadsworth MB, Pennell A, Phillips M, Vilar FJ. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 2011; 25: 1051-1056 [PMID: 21346511 DOI: 10.1097/QAD.0b013e328345ef5e]
80. ADHOC International Steering Committee. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Med 2002; 3: 229-238 [PMID: 12444940]
81. Milazzo L, Caramma I, Lai A, Violin M, De Maddalena C, Cesari M, Galli M, Balotta C. Telbivudine in the treatment of chronic hepatitis B: experience in HIV type-1-infected patients naive for antiretroviral therapy. Antivir Ther 2009; 14: 869-872 [PMID: 19812451 DOI: 10.3851/1303]
82. (OARAC) OoARAC. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. AIDS info website 2013. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
83. EACS European AIDS Clinical Society. EACS Guidelines Version 7.0. 2013 Available from: URL: http://www.eacsociety.org/Portals/0/Guidelines-Online-131014.pdf
84. Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G, Brown A, Castelino S, Cooke G, Fisher M, Geretti AM, James R, Kulasegaram R, Leen C, Mutimer D, Orkin C, Page E, Palfreeman A, Papineni P, Rodger A, Tong CY. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med 2013; 14 Suppl 4: 1-71 [PMID: 24581304 DOI: 10.1111/hiv.12106]
85. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180: 607-613 [PMID: 10438346 DOI: 10.1086/314942]
86. Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, Brinkman K, Meenhorst PL, de Man RA. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002; 24: 173-181 [PMID: 11856618]
87. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. Clin Infect Dis 2001; 32: 963-969 [PMID: 11247719 DOI: 10.1086/319368]
88. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-1306 [PMID: 10534354 DOI: 10.1002/hep.510300525]
89. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, Ng KY, Nicholls GJ, Dent JC, Leung NW. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-1282 [PMID: 15482535 DOI: 10.1111/j.1440-1746.2004.03428.x]
90. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, Cooper DA, Lewin S, Dore GJ, Thio CL. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863-870 [PMID: 16549970 DOI: 10.1097/01.aids.0000218550.85081.59]
91. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298-305 [PMID: 12823597]
92. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695 [PMID: 15987917 DOI: 10.1056/NEJMoa043470]
93. Neumann A, Polis M, Rozenberg L, Jackson J, Reitano K, McLaughlin M, Koratich C, Dewar R, Masur H, Haagmans B, Kottilil S. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV coinfected patients. AIDS 2007; 21: 1855-1865 [PMID: 17721093 DOI: 10.1097/QAD.0b013e32825eaba7]
94. Liu MQ, Zhou DJ, Wang X, Zhou W, Ye L, Li JL, Wang YZ, Ho WZ. IFN-λ3 inhibits HIV infection of macrophages through the JAK-STAT pathway. PLoS One 2012; 7: e35902 [PMID: 22558263 DOI: 10.1371/journal.pone.0035902]
95. Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, Solsky J, Torriani FJ, Dieterich D, Larrey D. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18: F21-F25 [PMID: 15316334]
96. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003; 39 Suppl 1: S111-S115 [PMID: 14708688]
97. Borroto-Esoda K, Parkin N, Miller MD. A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine. Antivir Chem Chemother 2007; 18: 297-300 [PMID: 18046962]
98. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-633 [PMID: 16152756]
99. Gish RG, Trinh H, Leung N, Chan FK, Fried MW, Wright TL, Wang C, Anderson J, Mondou E, Snow A, Sorbel J, Rousseau F, Corey L. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005; 43: 60-66 [PMID: 15922478 DOI: 10.1016/j.jhep.2005.02.017]
100. Nüesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS 2008; 22: 152-154 [PMID: 18090405 DOI: 10.1097/QAD.0b013e3282f303bf]
101. Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006; 78 Suppl 1: S52-S55 [PMID: 16622878 DOI: 10.1002/jmv.20608]
102. Thio CL, Locarnini S. Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev 2007; 9: 40-53 [PMID: 17474312]
103. Benhamou Y, Thibault V, Vig P, Calvez V, Marcelin AG, Fievet MH, Currie G, Chang CG, Biao L, Xiong S, Brosgart C, Poynard T. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006; 44: 62-67 [PMID: 16274835 DOI: 10.1016/j.jhep.2005.08.020]
104. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816 [PMID: 12606735 DOI: 10.1056/NEJMoa020681]
105. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751 [PMID: 17087951 DOI: 10.1053/j.gastro.2006.09.020]
106. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-1451 [PMID: 17983801 DOI: 10.1053/j.gastro.2007.08.079]
107. Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kobayashi M, Kumada H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008; 48: 923-931 [PMID: 18433925 DOI: 10.1016/j.jhep.2008.02.019]
108. Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-1192 [PMID: 15031786 DOI: 10.1086/380398]
109. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, Pillay D, Fisher M, Bower M, Gazzard B. An openlabel study of tenofovir in HIV-1 and Hepatitis B virus coinfected individuals. AIDS 2003; 17: F7-10 [PMID: 12478090 DOI: 10.1097/01.aids.0000042959.95433.c1]
110. Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, Peck-Radosavljevic M. Five-year ontreatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. J Viral Hepat 2012; 19: 801-810 [PMID: 23043387 DOI: 10.1111/j.1365-2893.2012.01601.x]
111. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One 2013; 8: e68152 [PMID: 23874527 DOI: 10.1371/journal.pone.0068152]
112. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505 [PMID: 20673002 DOI: 10.1086/655681]
113. Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A, Brett- Smith H. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008; 22: 1779-1787 [PMID: 18753861 DOI: 10.1097/QAD.0b013e32830b3ab5]
114. McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356: 2614-2621 [PMID: 17582071 DOI: 10.1056/NEJMoa067710]
115. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-3507 [PMID: 15328117 DOI: 10.1128/AAC.48.9.3498-3507.2004]
116. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588 [PMID: 18094378 DOI: 10.1056/NEJMoa066422]
117. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495 [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026]
118. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]
119. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010; 53: 348-356 [PMID: 20483498 DOI: 10.1016/j.jhep.2010.02.035]
120. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107 [PMID: 23213040 DOI: 10.1002/hep.26180]
121. Núñez M, Pérez-Olmeda M, Díaz B, Ríos P, González-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16: 2352-2354 [PMID: 12441815]
122. Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20: 1951-1954 [PMID: 16988516 DOI: 10.1097/01.aids.0000247116.89455.5d]
123. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-299 [PMID: 18657708 DOI: 10.1016/S0140-6736(08)61113-7]
124. Tuma P, Medrano J, Resino S, Vispo E, Madejón A, Sánchez-Piedra C, Rivas P, Labarga P, Martín-Carbonero L, Barreiro P, Soriano V. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther 2010; 15: 881-886 [PMID: 20834100 DOI: 10.3851/Imp1630]
125. Martín-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, González-Lahoz J, Soriano V. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011; 25: 73-79 [PMID: 21076274 DOI: 10.1097/Qad.0b013e328340fde2]
126. Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, Rauch A, Probst-Hensch NM, Bouchardy C, Levi F, Franceschi S. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22: 2135-2141 [PMID: 18832877 DOI: 10.1097/Qad.0b013e32831103ad]
127. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. Curr Opin Oncol 2009; 21: 445-454 [PMID: 19606034 DOI: 10.1097/Cco.0b013e32832f3e04]
128. Chelis L, Ntinos N, Souftas V, Deftereos S, Xenidis N, Chamalidou E, Maltezos E, Kakolyris S. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIVHBV co infected patient: Possible synergy with HAART ? A case report. Med Oncol 2011; 28 Suppl 1: S165-S168 [PMID: 20809183 DOI: 10.1007/s12032-010-9669-y]
129. Perboni G, Costa P, Fibbia GC, Morandini B, Scalzini A, Tagliani A, Cengarle R, Aitini E. Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. Oncologist 2010; 15: 142-145 [PMID: 20142333 DOI: 10.1634/theoncologist.2010-0010]
130. Ozenne V, Gervais A, Peytavin G, Castelnau C, Valla DC, Degos F. Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report. Hepatogastroenterology 2011; 58: 161-162 [PMID: 21510306]
131. Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, Ragni M, Regenstein FG, Sherman KE, Roland ME, Terrault NA. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010; 10: 1268-1275 [PMID: 20346065 DOI: 10.1111/j.1600-6143.2010.03070.x]
132. Tateo M, Roque-Afonso AM, Antonini TM, Medja F, Lombes A, Jardel C, Teicher E, Sebagh M, Roche B, Castaing D, Samuel D, Duclos-Vallee JC. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009; 23: 1069-1076 [PMID: 19417577 DOI: 10.1097/QAD.0b013e32832c2a37]
133. Solid Organ Transplant in HIV: Multi-Site Study. When to Start the Transplant Referral Process. Available from: URL: http://spitfire.emmes.com/study/htr/
134. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6-S9 [PMID: 16352363 DOI: 10.1016/j.jhep.2005.11.004]
135. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745 [PMID: 9392700 DOI: 10.1056/NEJM199712113372406]
136. Lopes VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, Schutten M, de Man RA, van der Ende ME. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine 2013; 31: 1040-1044 [PMID: 23273969 DOI: 10.1016/j.vaccine.2012.12.047]
137. Paitoonpong L, Suankratay C. Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scand J Infect Dis 2008; 40: 54-58 [PMID: 17852939 DOI: 10.1080/00365540701522975]
138. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204 [PMID: 8988900 DOI: 10.1056/NEJM199701163360307]
139. Irungu E, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, Dhanireddy S, Baeten JM. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. J Infect Dis 2013; 207: 402-410 [PMID: 23175769 DOI: 10.1093/infdis/jis695]
140. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23: 2902-2908 [PMID: 15780739 DOI: 10.1016/j.vaccine.2004.11.057]
141. Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, Libbrecht E, Wendling MJ, Vetter D, Nicolle M, Kempf-Durepaire G, Lang JM. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18: 1161-1165 [PMID: 10649616]
142. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41: 1045-1048 [PMID: 16142673 DOI: 10.1086/433180]
143. Tedaldi EM, Baker RK, Moorman AC, Wood KC, Fuhrer J, McCabe RE, Holmberg SD. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004; 38: 1478-1484 [PMID: 15156488 DOI: 10.1086/420740]
144. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008; 19: 600-604 [PMID: 18725550 DOI: 10.1258/ijsa.2007.007197]
145. Potsch DV, Oliveira ML, Ginuíno C, Miguel JC, Oliveira SA, Silva EF, Moreira RB, Cruz GV, Oliveira AL, Camacho LA, Barroso PF. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine 2010; 28: 1447-1450 [PMID: 19995540 DOI: 10.1016/j.vaccine.2009.11.066]
146. Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, Colin de Verdière N, Slama L, Martin K, Lortholary O, Carrat F. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011; 305: 1432-1440 [PMID: 21486976 DOI: 10.1001/jama.2011.351]
147. Cornejo-Juárez P, Volkow-Fernández P, Escobedo-López K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramírez LE. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther 2006; 3: 9 [PMID: 16600028 DOI: 10.1186/1742-6405-3-9]
148. Ungulkraiwit P, Jongjirawisan Y, Atamasirikul K, Sungkanuparph S. Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients. Southeast Asian J Trop Med Public Health 2007; 38: 680-685 [PMID: 17883006]
149. Chedid MG, Deulofeut H, Yunis DE, Lara-Marquez ML, Salazar M, Deulofeut R, Awdeh Z, Alper CA, Yunis EJ. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum Immunol 1997; 58: 42-51 [PMID: 9438208]
150. Shokrgozar MA, Shokri F. Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and nonresponder normal individuals vaccinated with recombinant hepatitis B surface antigen. Immunology 2001; 104: 75-79 [PMID: 11576223]
151. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004; 39: 978-988 [PMID: 15057902 DOI: 10.1002/hep.20142]
152. Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992; 14: 27-30 [PMID: 1532609]
153. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006; 24: 7124-7128 [PMID: 16884833 DOI: 10.1016/j.vaccine.2006.06.079]
154. Gandhi RT, Wurcel A, McGovern B, Lee H, Shopis J, Corcoran CP, Toner S, Giachetti C, Dockter J, Sax PE, Ukomadu C. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr 2003; 34: 439-441 [PMID: 14615664]
155. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36: 869-875 [PMID: 15213572]
156. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008; 122: 12-9; quiz 20-1 [PMID: 18547629 DOI: 10.1016/j.jaci.2008.04.034]
157. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis 2008; 12: e77-e83 [PMID: 18723381 DOI: 10.1016/j.ijid.2008.05.1226]
158. Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, Peel S, Agan BK. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009; 27: 4731-4738 [PMID: 19540026 DOI: 10.1016/j.vaccine.2009.04.016]
159. Winnock M, Neau D, Castera L, Viot J, Lacoste D, Pellegrin JL, Dupon M, Jutand MA, Colombani F, Dabis F. Hepatitis B vaccination in HIV-infected patients: a survey of physicians and patients participating in the Aquitaine cohort. Gastroenterol Clin Biol 2006; 30: 189-195 [PMID: 16565650]
160. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50: 1-43 [PMID: 11349873]
161. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004; 351: 2832-2838 [PMID: 15625334 DOI: 10.1056/NEJMcp041507]
162. Connor BA, Patron DJ. Use of an accelerated immunization schedule for combined hepatitis A and B protection in the corporate traveler. J Occup Environ Med 2008; 50: 945-950 [PMID: 18695453 DOI: 10.1097/JOM.0b013e3181808081]
163. Marchou B, Excler JL, Bourderioux C, Salaun J, Picot N, Yvonnet B, Cerisier JE, Salomon H, Auvergnat JC. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. J Infect Dis 1995; 172: 258-260 [PMID: 7797926]
164. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Kauffmann RH, Leyten EM, Mudrikova T, Brinkman K, den Hollander JG, Kroon FP, Janssen HL, van der Ende ME, de Man RA. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis 2011; 203: 984-991 [PMID: 21266513 DOI: 10.1093/infdis/jiq137]
165. Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, Silva EF, Mendonc¸a RM, Moreira RB, Barroso PF. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine 2012; 30: 5973-5977 [PMID: 22828589 DOI: 10.1016/j.vaccine.2012.07.028]
166. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Metaanalysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 2006; 24: 497-506 [PMID: 16886915 DOI: 10.1111/j.1365-2036.2006.03002.x]
167. Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL, Yu JY, Aberg JA. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocytemacrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine 2010; 28: 5597-5604 [PMID: 20600512 DOI: 10.1016/j.vaccine.2010.06.030]
168. Overton ET, Sungkanuparph S, Klebert M, Royal M, Demarco-Shaw D, Powderly WG, Aberg JA. GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. Open Virol J 2011; 5: 109-113 [PMID: 22043256 DOI: 10.2174/1874357901105010109]
169. Sasaki Md, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003; 21: 4545-4549 [PMID: 14575766]
170. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008; 46: 1310-1314 [PMID: 18444872 DOI: 10.1086/533467]
171. Gatanaga H, Hayashida T, Tanuma J, Oka S. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Clin Infect Dis 2013; 56: 1812-1819 [PMID: 23487374 DOI: 10.1093/cid/cit145]
172. Sheng WH, Chuang YC, Sun HY, Tsai MS, Chang SY, Hung CC, Chang SC. Prophylactic effect of lamivudine-based antiretroviral therapy on incident hepatitis B virus infection among HIV-infected patients. Clin Infect Dis 2013; 57: 1504-1506 [PMID: 23926178 DOI: 10.1093/cid/cit511]